Morgan Ebert, Executive Editor

The FDA has approved Tivicay PD (dolutegravir) to treat HIV-1 in newborns from birth, based on IMPAACT 2023 pharmacokinetic and safety data.

FDA De Novo authorization establishes Avulux lenses as an option for migraine-associated light sensitivity in patients aged 12 years and older.

FDA authorized Abbott's Libre Duo 10 Day, the first wearable that continuously tracks glucose and ketones, for patients 2 and older with diabetes.

FDA approved nipocalimab (Imaavy) for wAIHA in patients 12 and older, based on Phase 2/3 ENERGY trial data on durable hemoglobin response.

Nine societies outline 6 domains of hospital-level sepsis strategies, from rapid blood culture diagnostics to daily toothbrushing protocols.

Higher parent smartphone use was associated with slower vocabulary growth from ages 5 to 7 years in a prospective cohort study.

Infliximab or steroids may be more effective than anakinra as adjunctive therapy for children with MIS-C who do not respond to IVIG.

FDA granted priority review to Teva's ecopipam for pediatric Tourette syndrome, backed by phase 3 data showing reduced relapse risk.

Starting antiviral therapy within 48 hours of influenza symptom onset was associated with an 81% lower hospitalization risk in children.

A microbial metabolite, isovalerate, and its precursor leucine restored gut barrier function in malnourished mice, a preclinical study found.

A Rutgers-led study finds teens who follow beauty influencers or watch tutorials use significantly more personal care products, many containing endocrine-disrupting chemicals.

Pediatric psychologist Jeff Temple, PhD, explains how pediatricians can help families establish healthy routines and more intentional screen use.

A meta-analysis of 190 studies and 2.8 million children pinpoints eczema, delayed allergens, and antibiotics as top food allergy risks.

In 38 late preterm/early-term dyads, breast milk composition shifted by week 8 while maternal gut stayed stable, and infant gut Bifidobacterium rose.

New approvals and emerging data are expanding nonsteroidal topical treatment options for several chronic pediatric skin conditions.

Adverse childhood experiences may affect pediatric skin disease risk and outcomes, but researchers say evidence remains limited.

Scholar Rock says apitegromab's SMA BLA stays on track for its September 30, 2026, PDUFA date after dropping one of 2 fill-finish sites.

Executive order seeks to trim routine childhood vaccines, split combination shots, and push parent-doctor decisions—sparking debate as measles surges.

Revised Anaphylm packaging cut pouch-opening time from 17 to 3 seconds, and self-administered PK matched clinician-administered data.

FDA accepted Merck's sBLA extending ENFLONSIA (clesrovimab-cfor) to high-risk children under 2 in their second RSV season.

A look back at the FDA approvals, regulatory decisions, and pipeline updates in the pediatric health care space from July 2026.

A look back at the latest clinical trial updates for the pediatric population during July 2026.

A large prospective US cohort study found no evidence that neonatal medical male circumcision was associated with autism diagnosis or autism traits.

A systematic review found chronic pediatric skin disorders are consistently associated with psychological distress, reduced quality of life, and caregiver burden.

Poison center data show most water bead ingestions are mild, but children younger than 2 years face higher risk for serious outcomes.

Many families with a first-degree history of type 1 diabetes underestimate their risk, highlighting opportunities for pediatricians to discuss screening.

In the OUTMATCH trial, omalizumab achieved higher treatment success than multiallergen oral immunotherapy, largely because of fewer adverse events.

The FDA has approved novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine for ADHD in children, adolescents, and adults

FDA approved Tylenol with Naproxen, the first OTC fixed-dose acetaminophen/naproxen sodium tablet, for 12-hour pain relief in patients 12 and older.

A pooled ADORING trial analysis found tapinarof cream improved skin clearance by week 2 across ages 2 through adulthood in atopic dermatitis.